Testing associations between cannabis use and subcortical volumes in two large population-based samples

Nathan A. Gillespie1,2, Michael C. Neale1, Timothy C. Bates3, Lisa T. Eyler4,5, Christine Fennema-Notestine5, Jasmin Vassileva6, Michael J. Lyons7, Elizabeth C. Prom-Wormley8, Katie L. McMahon9, Paul M. Thompson9, Greig deZubicaray10,11, Ian B. Hickie12, John J. McGrath13,14, Lachlan T. Strike2,9,10, Miguel E. Rentería2, Matthew S. Panizzon5, Nicholas G. Martin2, Carol E. Franz5, William S. Kremen5,14 & Margaret J. Wright2,9*

Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, VA, USA,1 QIMR Berghofer Medical Research Institute, QLD, Australia,2 Department of Psychology, University of Edinburgh, EH8 9JZ, UK,3 Desert-Pacific Mental Illness Research, Education and Clinical Center, VA San Diego Healthcare System, CA, USA,4 Department of Psychiatry, University of California San Diego, CA, USA,5 Institute for Drug and Alcohol Studies, Virginia Commonwealth University, VA, USA,6 Department of Psychological and Brain Sciences, Boston University, Boston, MA, USA,7 Department of Family Medicine and Population Health, Virginia Commonwealth University, VA, USA,7 Centre for Advanced Imaging, The University of Queensland, QLD, Australia,8 School of Psychology, The University of Queensland, QLD, Australia,9 Faculty of Health and Institute of Biomedical Innovation, Queensland University of Technology, Brisbane, Australia,10 Brain and Mind Research Institute, University of Sydney, NSW, Australia,11 Queensland Brain Institute, The University of Queensland, QLD, Australia,12 and VA San Diego Center of Excellence for Stress and Mental Health, CA, USA,13

ABSTRACT

Background and aims Disentangling the putative impact of cannabis on brain morphology from other comorbid substance use is critical. After controlling for the effects of nicotine, alcohol and multi-substance use, this study aimed to determine whether frequent cannabis use is associated with significantly smaller subcortical grey matter volumes.

Design Exploratory analyses using mixed linear models, one per region of interest (ROI), were performed whereby individual differences in volume (outcome) at seven subcortical ROIs were regressed onto cannabis and comorbid substance use (predictors).

Setting Two large population-based twin samples from the United States and Australia.

Participants A total of 622 young Australian adults (66% female; \(\mu_{\text{age}} = 25.9, \text{standard deviation SD} = 3.6\)) and 474 middle-aged US males (\(\mu_{\text{age}} = 56.1, \text{SD} = 2.6\)) of predominately Anglo-Saxon ancestry with complete substance use and imaging data. Subjects with a history of stroke or traumatic brain injury were excluded.

Measurements Magnetic resonance imaging (MRI) and volumetric segmentation methods were used to estimate volume in seven subcortical ROIs: thalamus, caudate nucleus, putamen, pallidum, hippocampus, amygdala and nucleus accumbens. Substance use measurements included maximum nicotine and alcohol use, total lifetime multi-substance use, maximum cannabis use in the young adults and regular cannabis use in the middle-aged males.

Findings After correcting for multiple testing (\(P = 0.007\)), cannabis use was unrelated to any subcortical ROI. However, maximum nicotine use was associated with significantly smaller thalamus volumes in middle-aged males.

Conclusions In exploratory analyses based on young adult and middle-aged samples, normal variation in cannabis use is unrelated statistically to individual differences in brain morphology as measured by subcortical volume.

Keywords Brain volume, cannabis use, grey matter, imaging, multi-substance use, subcortical.

INTRODUCTION

Cannabis is used commonly by adolescents and young adults [1], and if used frequently can be potentially hazardous to mental health. During development, there are dynamic changes in brain neurochemistry, fibre architecture and tissue composition [2], which could be impacted by chronic cannabis use (CU) or comorbid...
substance use (SU), such as nicotine and alcohol [3]. In view of changing cultural norms, and expanding cannabis medicalization and decriminalization, disentangling the potential impact of cannabis on brain morphology from other substances is critical.

In contrast to the psychiatric and social consequences of cannabis use [4], our knowledge of the morphological changes associated with cannabis use is not well characterized. Whereas infrequent or regular adult cannabis use does not appear to affect neurological functioning [5], chronic cannabis use appears to affect cognition in adults [5]. Among adolescents and young adults, cannabis use is associated with enduring cognitive decline [6]. This suggests that cannabis use probably affects or is associated with changes in brain morphology.

Grey matter volume (GMV) is a widely used indicator of brain morphology. We reviewed 24 studies [7–30], one review [31] and one meta-analysis [32] examining GMV and SU. Varying by region, six studies reported greater GMV related to SU [10,13,15,28,29], one found no difference [14], while the remainder identified smaller GMVs in relation to more frequent SU. Among the regions of interest (ROI), the putamen, hippocampus and thalamus subcortical structures have emerged as putative markers for SU. However, findings have been equivocal and vary by substance. We reviewed eight reports identifying smaller putamen volumes among heavy alcohol [8,9,22], nicotine [12], cannabis [24], cocaine [17,23] and ecstasy [33] users, compared to three reports identifying larger putamen volumes among methamphetamine [10] and nicotine users [28,29]. Ten reports have identified reductions in hippocampus volume associated with alcohol [9,25], nicotine [12,34], methamphetamines [26] and cannabis [7,27,30,34,35], compared to one report that found no association with alcohol use [14]. Several reports have also linked smaller thalamus volume to increased alcohol [8,22], nicotine [28], methamphetamines [26] and opioid [18] use compared to one that identified larger thalamus volumes among cannabis users [13].

The above studies vary widely in terms of their image acquisition, selection of regions, volume estimation methods and statistical control for comorbid SU. Because cannabis use is highly comorbid with a variety of licit and illicit substance use [36], the need to disentangle the putative effects of alcohol, nicotine or multi-substance use (MSU) is critical. For example, alcohol use is associated with smaller hippocampus, thalamus, putamen and pallidum volumes [8,9,22,25], whereas studies investigating the associations between nicotine use and subcortical volumes are equivocal [12,28,29,37]. Less is known about the effects of poly- or multi-substance use (MSU) [38], with evidence suggestive of smaller subcortical volumes in regions such as the thalamus [39] and the putamen [40]. However, another major limitation is sample size. In 21 reports investigating associations between licit or illicit SU and subcortical volumes in one or more regions, the average sample size was 90 [8–10,12–15,17,18,22–29,35,41–43]. Consequently, larger imaging samples that include measures of cannabis and comorbid SU are required.

The aim of this report is to determine the size of associations between cannabis use and the volumes of seven subcortical ROIs in two independent population-based samples. We hypothesize that increased cannabis use will be associated with smaller subcortical volumes over and above the effects of comorbid nicotine, alcohol and life-time multi-substance use.

**METHODS**

**Design**

Our approach relied upon data from two samples with similar phenotypical measures.

We began by measuring the strength of associations between nicotine, alcohol, multi-substance use, cannabis use and subcortical volumes at seven ROIs. We performed exploratory analyses to determine the relationship between cannabis use and volume. Specifically, we regressed each subcortical ROI onto nicotine, alcohol, multi-substance and cannabis use using mixed linear models. For each sample, we fitted one regression for every ROI. All results were adjusted for multiple testing.

**Sample 1**

**Participants**

Sample 1 comprised 622 young male and female adult twins from the ongoing population-based Brisbane Longitudinal Twin Study (BLTS) [44,45]. The participants were of European ancestry, predominantly Anglo-Saxon, who were ascertained beginning 1992 to study of melanocytic naevi, and have since been followed-up on multiple occasions.

**Procedure**

Between 2009 and 2015 the BLTS subjects participated in an on-line survey of substance use [66% female; μ_{age} = 25.9, standard deviation (SD) = 3.6, range = 18–38] [44,45]. Almost 3 years prior, the participants were scanned with magnetic resonance imaging (MRI) (μ_{age} = 23.0, SD = 2.8, range = 18–30) as part of the Queensland Twin Imaging study [46]. There were 27 and 29 subjects whose onset ages at cannabis initiation and heaviest cannabis use, respectively, occurred after scanning. These subjects were excluded. Only subjects whose age at cannabis initiation or age at heaviest cannabis use preceded or occurred during the scanning year were included in the analyses.
Informed consent was obtained from all participants who received an honorarium of AUD$50 for completion of the survey, and $100 for MRI participation to defray travel costs.

Measures

Substance use. The on-line survey included maximum cannabis use, which assessed the time or times when cannabis was used the most (never used, once or twice, monthly, weekly and daily or almost daily), maximum nicotine use based on the total number of cigarettes smoked life-time (never used, one to two times, three to five times, six to 10 times, 11–15 times, 16–19 times, 20–25 times, 26–99 times, 100–199 times and ≥ 200 times), maximum alcohol use based on the period when drinking the most how often subjects consumed four (female) or five (male) or more drinks at least once a week for a month or more, and total life-time multi-substance use (MSU) based on having ever tried or used the following nine substances: cocaine; amphetamine-type stimulants (speed, ice, diet pills, etc.); inhalants (nitrous, glue, petrol, paint thinner, etc.); sedatives or sleeping pills (valium, serexap, Rohypnol, etc.); hallucinogens [lysergic acid diethylamide (LSD), acid, mushrooms, phencyclidine (PCP), etc.]; opioids (heroin, morphine, methadone, codeine, etc.); ecstasy, ketamine, γ-hydroxybutyric acid (GHB) or party drugs (E, X, 3,4-methylenedioxymethamphetamine (MDMA), K, Special K, Fantasy; over-the-counter/prescription painkillers and analgesics for non-medical purposes (e.g. cough medicine, mersyndol, ibuprofen, panadol, panadeine, codeine, hydrocodone, etc.); and over-the-counter/prescription stimulants for non-medical purposes (e.g. no doze, pseudoephedrine, dexamphetamine, Ritalin, etc.). In the Supporting information, we demonstrate that the construct of life-time multi-substance use is psychometrically homogeneous and possesses good internal reliability and concurrent validity. We also show that familial aggregation in multi-substance use is entirely attributable to genetic risk factors shared between siblings, and account for 51% of the total variance (Supporting information, Table S1). All other substance use descriptives are shown Table 1.

Imaging. Described in detail elsewhere [47], MRI images were acquired on a 4 T Bruker Medspec Scanner at the Center for Magnetic Resonance, University of Queensland, Australia using an inversion recovery rapid gradient echo protocol. Total intracranial volume and the volumes of 14 subcortical structures were extracted: thalamus; caudate nucleus; putamen; pallidum; hippocampus; amygdala; and nucleus accumbens. Quality of delineation was assessed following the Enhancing Neuro-Imaging Genetics through Meta-Analysis consortium protocol for subcortical structures (http://enigma.loni.ucla.edu/protocols/imaging-protocols/quality-checking-subcortical-structures), which resulted in the exclusion of 1.83% of volumes segmented with Freesurfer (version 5.3). As discussed by Fischl [48], images were skull-stripped, transformed to Talairach space and a probabilistic atlas was used to assign each voxel a neuroanatomical label. Prior to scanning, all participants were screened by self-report for imaging suitability, including significant medical, psychiatric or neurological conditions (including head injuries) and current use of psychoactive medication. As shown in Table 2, in sample 1 the correlations between the mean volumes of the homologous left and right subcortical ROIs were high and ranged from 0.60 to 0.93. Therefore, we averaged the left and right homologous ROIs and analysed the residuals after adjusting for age and total intracranial volume. Because of the higher prevalence of cannabis use among males [49], residuals were also adjusted for sex.

Sample 2

Participants

Sample 2 comprised 474 middle-aged male twins from the population-based Harvard Drug Study (HDS) [50] who were scanned with MRI as part of the Vietnam Era Twin Study of Aging (VETSA) between 2003 and 2007 [51,52]. Participants were concordant for US military service at some time between 1965 and 1975. Nearly 80% reported no combat experience. The sample was 88.3% non-Hispanic white, 5.3% African American, 3.4% Hispanic and 3.0% ‘other’ participants. Based on data from the US National Center for Health Statistics, the sample was very similar to American men in their age range with respect to health and life-style characteristics [53]. Written informed consent was obtained from all participants. The local ethics committee approved the study.

Procedure

Phenotypical data were collected as part of the HDS in 1992 (μage = 44.6, SD = 2.5) by telephone interview from members of the Vietnam Era Twin Registry, comprising male twin pairs who served in the US military between 1965 and 1975 [50]. The VETSA is a longitudinal behavioural genetic study with a primary focus on cognitive and brain ageing in men. It comprises a subset of more than 1200 twins from the Vietnam Era Twin Registry [51]. A companion VETSA project included the administration of MRIs twice to a subset of participants. MRI data for this report came from the first MRI (VETSA1) in which twins (μage = 56.1, SD = 2.6, range = 51.1–60.2) underwent three-dimensional (3D) structural MRIs to measure cortical and subcortical volumes, cortical thickness and surface area. The minimum difference between age at first
cannabis initiation and scanning was 20.2 years. Exclusion criteria included stroke, traumatic brain injury (TBI) and brain tumours. A total of 14 and 36 subjects who reported stroke and TBI, respectively, at the time of scanning were excluded from our analyses.

### Measures

**Substance use.** The HDS in 1992 assessed regular cannabis use based on having ever used regularly once per week or more (0 = no, 1 = yes). All never users were coded as zero. Other substance use measures included maximum

<table>
<thead>
<tr>
<th>Table 1 Distribution of substance use measures for young adults (sample 1) and middle-aged males (sample 2).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age of cannabis initiation</strong></td>
</tr>
<tr>
<td><strong>Males</strong></td>
</tr>
<tr>
<td>μ = 17.5 years,</td>
</tr>
<tr>
<td>SD = 2.8,</td>
</tr>
<tr>
<td>range = 10–32</td>
</tr>
</tbody>
</table>

**Maximum cannabis use**
- When using the most how often did you use it?
  - Never used: 370 Males, 678 Females
  - Once or twice: 258 Males, 324 Females
  - Monthly: 52 Males, 45 Females
  - Weekly: 64 Males, 44 Females
  - Daily or almost daily: 94 Males, 56 Females

**Regular cannabis use**
- Have you ever used marijuana regularly once per week or more?
  - No: –
  - Yes: – 359 Males

**Maximum alcohol use**
- When drinking the most how often did you consume ≥ 4 (female) or ≥ 5 (male) drinks at least once a week for a month or more?
  - Never drank: 11 Males, 23 Females
  - Consumed < 4 (female)/< 5 (male) drinks: 312 Males, 528 Females
  - Consumed ≥ 4 (female)/≥ 5 (male) drinks: 676 Males, 797 Females

**Maximum nicotine use**
- Total number of cigarettes smoked life-time
  - Never: 374 Males, 678 Females
  - 1–2 times: 66 Males, 78 Females
  - 3–5 times: 61 Males, 79 Females
  - 6–10 times: 39 Males, 55 Females
  - 11–15 times: 28 Males, 33 Females
  - 16–19 times: 12 Males, 19 Females
  - 20–25 times: 35 Males, 30 Females
  - 26–99 times: 64 Males, 68 Females
  - 100–199 times: 39 Males, 47 Females
  - ≥ 200 times: 281 Males, 263 Females

**Cigarettes per day when smoking the most**
- Never: –
- 1–15: –
- 16–20: –
- 21–30: –
- 31–40: –
- ≥ 41: –

**Multi-substance use**
- μ = 1.4, SD = 2.1, range = 0–10
- μ = 1.1, SD = 1.8, range = 0–10
- μ = 0.7, SD = 1.4, range = 0–5

SD = standard deviation.
nicotine use based on the number of cigarettes smoked per day during the heaviest period (never used, one to two times, three to five times, six to 10 times, 11–15 times, 41–99 times), maximum alcohol use based on the number of days drinking per month when drinking the heaviest and life-time multi-substance use based on having ever tried the following five substances: stimulants; sedatives; cocaine; heroin; and PCP or other psychedelics. Substance use descriptives are shown Table 1.

**Imaging.** Between 2003 and 2007, the VETSA [51] acquired brain imaging on Siemens 1.5 Tesla scanners at University of California, San Diego, and at Massachusetts General Hospital. Sagittal T1-weighted MPRAGE sequences were employed with the following acquisition parameters: TI = 1000 ms, TE = 3.31 ms, TR = 2730 ms, flip angle = 7 degrees, 13 slice thickness = 1.33 mm and voxel size 1.3 × 1.0 × 1.3 mm. Images were corrected automatically for spatial distortion caused by gradient non-linearity and B1 field inhomogeneity. Two T1-weighted images per subject were registered and averaged to improve signal-to-noise. Volumetric segmentation [54,55] methods were based on FreeSurfer (FS version 3.0.1b). The semi-automated, fully 3D whole-brain segmentation procedure uses a probabilistic atlas and applies a Bayesian classification rule to assign a neuroanatomical label to each voxel [56]. A widely used training atlas has been shown to be comparable to that of expert manual labelling [56], but we created a VETSA-specific atlas that increased accuracy further compared to expert manual labelling [57].

As shown in Table 2, in sample 2 the correlations between the mean volumes of the homologous left and right subcortical ROIs ranged from 0.54 to 0.90. Again, we averaged the left and right homologous ROIs, and analysed the residuals after adjusting for age, total intracranial volume and MRI site.

**Statistical analyses**

**Measures of association.** Measures of association between substance use and the volume at each ROI were based on polyserial correlations estimated using the OpenMx software package [58] in R version 3.1.1 [59]. Polyserial correlations represent the inferred latent correlations between the continuous subcortical volumes and the ordered categorical SU variables.

**Mixed linear models.** To determine the contribution of cannabis and comorbid substance use to volume we fitted mixed linear models. Specifically, all models were conducted in a multi-level framework, using the lme function from the nlme package [60]. Our rationale was to model the random effects to adjust for the presence of correlated observations in twin data. In each model, family ID and zygosity to denote whether twins were part of a genetically identical monozygotic or dizygotic twin pair were entered as the random effect. For each sample, we then performed seven regressions using a corrected P-value threshold of 0.007.

**RESULTS**

**Sample 1**

Across sex, the average age at cannabis initiation was 17.7, SD = 2.8 in the young adults, while the average age at which cannabis was used the most was 18.2, SD = 4.11. The number of pairwise observations, along with polychoric correlations, is shown in Table 3. Depending on the region, the number of subjects with complete volume and maximum cannabis use data ranged from 618 to 622. Correlations between subcortical volumes and the cannabis use measures were all small, ranging from $r = -0.06$ to $r = +0.05$, each with relatively large standard errors. The correlations between each of the subcortical regions and nicotine, alcohol and multi-substance use (MSU) were also small. Among the larger negative correlations, maximum alcohol and multi-substance use were each associated with smaller hippocampus volume ($r = -0.07$). A life-time history of greater multi-substance use was also associated with a smaller pallidum ($r = -0.08$) volume.

Mixed-model linear regression results for the middle-aged males appear in Table 4. Commensurate with the polyserial correlations, maximum cannabis use was unrelated to volume at each ROI. There were, however, nominal associations ($P < 0.01$) between smaller hippocampus volumes and increased multi-substance use as well as maximum cannabis use.

**Sample 2**

In the middle-aged males, the average age at cannabis initiation was 20.2, SD = 3.5, while the average age at which they first used cannabis more than five times was 20.4, SD = 3.1. The numbers of pairwise observations and polychoric correlations are shown in Table 5. Depending on the region, the number of participants with complete
Table 3 The number of pairwise observations (upper diagonal), polychoric correlations and (standard errors) in the young Australian adults (sample 1); correlations between substance and volumes are shaded.

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Maximum nicotine use</td>
<td>0.61 (0.01)</td>
<td>2346</td>
<td>2346</td>
<td>2346</td>
<td>762</td>
<td>758</td>
<td>762</td>
<td>762</td>
<td>760</td>
<td>762</td>
<td>762</td>
</tr>
<tr>
<td>3. Maximum alcohol use</td>
<td>0.29 (0.02)</td>
<td>0.32 (0.01)</td>
<td>2366</td>
<td>2366</td>
<td>770</td>
<td>766</td>
<td>770</td>
<td>770</td>
<td>768</td>
<td>770</td>
<td>770</td>
</tr>
<tr>
<td>4. Multi-substance use</td>
<td>0.62 (0.01)</td>
<td>0.44 (0.01)</td>
<td>0.25 (0.02)</td>
<td>2862</td>
<td>849</td>
<td>845</td>
<td>849</td>
<td>849</td>
<td>847</td>
<td>849</td>
<td>849</td>
</tr>
<tr>
<td>5. Putamen volume</td>
<td>0.03 (0.04)</td>
<td>0.00 (0.04)</td>
<td>0.00 (0.04)</td>
<td>-0.07 (0.04)</td>
<td>0.00 (0.04)</td>
<td>0.35 (0.03)</td>
<td>849</td>
<td>845</td>
<td>845</td>
<td>843</td>
<td>845</td>
</tr>
<tr>
<td>6. Caudate volume</td>
<td>0.02 (0.05)</td>
<td>0.00 (0.04)</td>
<td>0.02 (0.04)</td>
<td>0.00 (0.04)</td>
<td>0.35 (0.03)</td>
<td>845</td>
<td>845</td>
<td>845</td>
<td>845</td>
<td>844</td>
<td></td>
</tr>
<tr>
<td>7. Pallidum volume</td>
<td>-0.04 (0.04)</td>
<td>-0.04 (0.04)</td>
<td>-0.04 (0.04)</td>
<td>-0.08 (0.03)</td>
<td>0.11 (0.03)</td>
<td>0.35 (0.03)</td>
<td>849</td>
<td>849</td>
<td>847</td>
<td>849</td>
<td>849</td>
</tr>
<tr>
<td>8. Hippocampus volume</td>
<td>-0.01 (0.04)</td>
<td>-0.01 (0.04)</td>
<td>-0.07 (0.04)</td>
<td>-0.07 (0.04)</td>
<td>0.17 (0.03)</td>
<td>0.11 (0.03)</td>
<td>0.26 (0.03)</td>
<td>849</td>
<td>847</td>
<td>849</td>
<td>849</td>
</tr>
<tr>
<td>9. Amygdala volume</td>
<td>0.04 (0.04)</td>
<td>0.02 (0.04)</td>
<td>0.00 (0.04)</td>
<td>0.00 (0.04)</td>
<td>0.29 (0.03)</td>
<td>0.17 (0.03)</td>
<td>0.22 (0.03)</td>
<td>0.37 (0.03)</td>
<td>847</td>
<td>847</td>
<td>846</td>
</tr>
<tr>
<td>10. Accumbens volume</td>
<td>-0.01 (0.04)</td>
<td>-0.01 (0.04)</td>
<td>0.00 (0.04)</td>
<td>0.01 (0.04)</td>
<td>0.17 (0.03)</td>
<td>0.29 (0.03)</td>
<td>0.25 (0.03)</td>
<td>0.15 (0.03)</td>
<td>0.29 (0.03)</td>
<td>849</td>
<td>849</td>
</tr>
<tr>
<td>11. Thalamus volume</td>
<td>0.02 (0.04)</td>
<td>0.05 (0.04)</td>
<td>-0.01 (0.04)</td>
<td>0.01 (0.04)</td>
<td>0.35 (0.03)</td>
<td>0.17 (0.03)</td>
<td>0.31 (0.03)</td>
<td>0.35 (0.03)</td>
<td>0.21 (0.03)</td>
<td>0.15 (0.03)</td>
<td>848</td>
</tr>
</tbody>
</table>

Maximum cannabis use = frequency of cannabis use when using the most (never used, once or twice, monthly, weekly and daily or almost daily); maximum nicotine use = total life-time cigarettes ever smoked; maximum alcohol use = when drinking the most have consumed four (female) or five (male) or more drinks at least once a week for a month or more; multi-substance use = total life-time use of cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, ecstasy [including ketamine, γ-hydroxybutyric acid (GHB) or party drugs], non-medical use of over-the-counter/prescription analgesics and non-medical use of over-the-counter/prescription stimulants.

Table 4 Standardized regression parameters for the mixed model linear regression models at each of the seven regions of interest for young Australian male and female adults (sample 1).

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Putamen B</th>
<th>Putamen P-value</th>
<th>Caudate B</th>
<th>Caudate P-value</th>
<th>Pallidum B</th>
<th>Pallidum P-value</th>
<th>Hippocampus B</th>
<th>Hippocampus P-value</th>
<th>Amygdala B</th>
<th>Amygdala P-value</th>
<th>Accumbens B</th>
<th>Accumbens P-value</th>
<th>Thalamus B</th>
<th>Thalamus P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum nicotine use</td>
<td>-0.01 P = 0.60</td>
<td>0.02 P = 0.39</td>
<td>0.02 P = 0.16</td>
<td>-0.01 P = 0.59</td>
<td>0.01 P = 0.72</td>
<td>0.00 P = 0.98</td>
<td>0.03 P = 0.07</td>
<td>0.11 P = 0.24</td>
<td>0.02 P = 0.78</td>
<td>0.02 P = 0.42</td>
<td>0.01 P = 0.68</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td></td>
</tr>
<tr>
<td>Maximum alcohol use</td>
<td>-0.05 P = 0.58</td>
<td>0.02 P = 0.80</td>
<td>-0.13 P = 0.17</td>
<td>-0.13 P = 0.13</td>
<td>-0.11 P = 0.21</td>
<td>-0.02 P = 0.42</td>
<td>-0.01 P = 0.68</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td></td>
</tr>
<tr>
<td>Multi-substance use</td>
<td>-0.04 P = 0.16</td>
<td>-0.02 P = 0.27</td>
<td>-0.06 P = 0.04</td>
<td>-0.07 P = 0.01</td>
<td>-0.03 P = 0.31</td>
<td>-0.02 P = 0.42</td>
<td>-0.01 P = 0.68</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td></td>
</tr>
<tr>
<td>Maximum cannabis use</td>
<td>0.06 P = 0.23</td>
<td>0.03 P = 0.54</td>
<td>0.03 P = 0.64</td>
<td>0.12 P = 0.02</td>
<td>0.10 P = 0.07</td>
<td>0.00 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td>0.09 P = 0.93</td>
<td>0.01 P = 0.92</td>
<td></td>
</tr>
</tbody>
</table>

β = standardized beta coefficients; Bonferroni-corrected P-value significance threshold = 0.007; maximum nicotine use = total life-time cigarettes ever smoked; maximum alcohol use = when drinking the most have consumed four (female) or five (male) or more drinks at least once a week for a month or more; multi-substance use = total life-time use of cocaine, amphetamines, inhalants, sedatives, hallucinogens, opioids, ecstasy [including ketamine, γ-hydroxybutyric acid (GHB) or party drugs], non-medical use of over-the-counter/prescription analgesics and non-medical use of over-the-counter/prescription stimulants; maximum cannabis use = frequency of cannabis use when using the most (never used, once or twice, monthly, weekly and daily or almost daily).
Table 5  The number of pairwise observations (upper diagonal), polychoric correlations and (standard errors) in middle-aged US males (sample 2); correlations between substance and volumes are shaded.

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Regular cannabis use</td>
<td>4.74</td>
<td>4.74</td>
<td>4.42</td>
<td>4.74</td>
<td>4.68</td>
<td>4.70</td>
<td>4.74</td>
<td>4.63</td>
<td>4.71</td>
<td>4.73</td>
<td>4.72</td>
</tr>
<tr>
<td>2. Maximum nicotine use</td>
<td>0.23 (0.01)</td>
<td>0.29 (0.03)</td>
<td>0.31 (0.03)</td>
<td>0.30 (0.06)</td>
<td>0.31 (0.04)</td>
<td>0.29 (0.05)</td>
<td>0.31 (0.04)</td>
<td>0.29 (0.05)</td>
<td>0.31 (0.04)</td>
<td>0.29 (0.05)</td>
<td>0.31 (0.04)</td>
</tr>
<tr>
<td>3. Maximum alcohol use</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>4. Putamen volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>5. Caudate volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>6. Pallidum volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>7. Hippocampus volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>8. Amygdala volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>9. Accumbens volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
<tr>
<td>10. Thalamus volume</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
<td>0.00 (0.06)</td>
</tr>
</tbody>
</table>

Regular cannabis use = frequency of cannabis use when using the most (never used, once or twice, monthly, weekly and daily or almost daily); maximum nicotine use = total life-time cigarettes ever smoked; maximum alcohol use = number of days drinking per month when drinking the heaviest; multi-substance use = total life-time use of stimulants, sedatives, cocaine, heroin and phencyclidine (PCP) or other psychedelics.

This is the largest exploratory analysis to our knowledge. To our knowledge, this is the largest exploratory analysis to our knowledge.
Table 6  Standardized regression parameters for the mixed-model linear regression models at each of the seven regions of interest for middle-aged males (sample 2).

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Thalamus β P-value</th>
<th>Amygdala β P-value</th>
<th>Basal ganglia β P-value</th>
<th>Hippocampus β P-value</th>
<th>Amygdala β P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum nicotine use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.04</td>
<td>0.15 P &lt; 0.001</td>
<td>0.03 P &lt; 0.001</td>
<td>0.03 P = 0.53</td>
<td>0.05 P = 0.87</td>
<td>0.03 P = 0.67</td>
</tr>
<tr>
<td>Maximum alcohol use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.88</td>
<td>0.02 P = 0.044</td>
<td>0.02 P = 0.035</td>
<td>0.02 P = 0.64</td>
<td>0.03 P = 0.023</td>
<td>0.02 P = 0.70</td>
</tr>
<tr>
<td>Multi-substance use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.50</td>
<td>0.02 P = 0.045</td>
<td>0.02 P = 0.026</td>
<td>0.02 P = 0.66</td>
<td>0.03 P = 0.023</td>
<td>0.02 P = 0.72</td>
</tr>
<tr>
<td>Regualr cannabis use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P = 0.70</td>
<td>0.02 P = 0.045</td>
<td>0.02 P = 0.026</td>
<td>0.02 P = 0.66</td>
<td>0.03 P = 0.023</td>
<td>0.02 P = 0.72</td>
</tr>
</tbody>
</table>

correlations illustrate that the effect sizes of cannabis use on volume at each ROI remain small and account for very little covariance.

Because our analyses were exploratory, we employed a Bonferroni-corrected P-value threshold of 0.007. There was a nominal association between increased cannabis use and smaller hippocampus volumes in the young adult sample. One might predict that the lack of any statistically significant main effect of cannabis use or other substances in the young adults is indicative of insufficient cumulative exposure to the detrimental effects prior to scanning. However, there was no effect of cannabis use among the middle-aged males who ought to have had longer cumulative exposure. Instead, only maximum nicotine use predicted smaller thalamus volumes significantly in the middle-aged males. If typical cigarette smoking is in the range of 20–40 per day, and if cannabis smoking is 10–20% of this quantity, then cannabis use is unlikely to result in any detectable volumetric differences. Of course, a longer exposure to cannabis per se may not predict volume if initiation occurred after a developmentally sensitive period. Battistella et al. [7] found marginally larger GMV reduction among early cannabis initiators. Striatal plasticity peaks during adolescence [62]. Therefore, a combination of early cannabis initiation and frequent cannabis use could result in reduced GMV due to plasticity loss at excitatory synapses [63].

We recommend caution when comparing the findings directly between samples. In addition to the different imaging methods, techniques employed there are measurement artefacts, as well as sex and cohort differences, in SU [64]. For example, multi-substance use in the young adults was based on substances including methamphetamine—a resurgence drug [65], and non-medical use of prescription stimulants and analgesics—a recent phenomenon [66], versus multi-substance use in the middle-aged males whose rates of cocaine, sedative and stimulant use were probably higher [64]. Maximum nicotine use was assessed differently in each sample: total life-time use in the younger adults versus multi-substance use in the middle-aged males. Data harmonization is required before direct comparisons can be made. Regarding sex differences, although the literature now supports sexual dimorphism [67], larger samples are again required to test for these effects. We nevertheless re-ran all seven mixed linear models, and each case, neither the main effect of sex nor the interaction between sex and maximum cannabis, was significant at our corrected P-value of 0.007. There was however, a nominal interaction between sex and cannabis (β = −0.13, P = 0.07) for the putamen.

Regarding the effect of MSU, it was only nominally predictive of smaller pallidum and hippocampus volumes in the young adults. This is inconsistent with Rodrigues et al. [68], who found that the cannabinoid subtype-1 and the μ-opioid receptors are targeted to some of the same
postsynaptic neurones in the rat putamen–caudate nucleus. The putamen and caudate form the dorsal striatum which, in addition to coordinating body movements, is involved in reward and decision-making, notably in relation to sensitivity to reward and habit formation [69]. In a covariance analysis of subcortical volumes, we have identified previously four distinct genetic factors, including a basal ganglia/thalamic factor comprising the putamen, caudate, pallidum and thalamus [70]. To the extent that striatal morphology may serve as a biomarker for neurodegenerative disease via substance use in general, this was not supported by our results.

Although nicotine did not predict putamen volume significantly in middle-aged males ($P = 0.04$), the nicotine–putamen correlation was nevertheless among the highest ($r = 0.12$). When considered with the significant nicotine–thalamus association, these results are consistent with prior findings. For example, Froeliger et al. [12] found that smoking abstinence was associated with higher preQUIT GMV in the putamen as well as the hippocampus. Vafaee et al. [71] observed significant global impairment in terms of cerebral blood flow and metabolic rate of oxygen in abstaining smokers in the left putamen and thalamus. Other studies have reported associations between nicotine phenotypes and the thalamus [28,72]. The putamen, thalamus and hippocampus all contain large numbers of neuronal nicotinic acetylcholine receptors [73], which have been associated with risk for nicotine dependence during adulthood [74].

**LIMITATIONS**

Our findings must be interpreted in the context of four potential limitations. First, compared to the middle-aged males, the young adult sample was scanned much closer to the mean ages of cannabis initiation and period of heaviest use. Because assessment age can bias recollection [75], more accurate recall is expected in the younger participants. It is plausible that the absence of any significant findings in these young adults can be attributed to their not having accumulated sufficient exposure to the putative detrimental effects of substance use on brain morphology.

Secondly, this study examined subcortical regions of interest. Hence, our results should not be generalized to other brain morphologies, including individual differences in cortical regions.

Thirdly, multi-substance use was based on the total number of substances ever tried in a lifetime, not including nicotine, alcohol and cannabis. The association between our validated measure of multi-substance use (see Supporting information) and volume may be driven by the frequency and quantity of use of one or more of these substances. In follow-up hierarchical regression analyses, measures of frequency of use for each of these covariates were not associated with volume at any ROI. Finally, our data were neither experimental nor longitudinal. It is possible that smaller subcortical volumes predispose individuals to increased SU. In the case of the middle-aged males, it is plausible that having a smaller thalamus is a causal risk factor for greater nicotine use. Commensurate with this idea, Squeglia et al. [76] found that pre-existing volume differences in frontal brain regions predicted future alcohol use, including further volume reductions in alcohol using teenagers. Pre-existing morphological differences could also arise *in utero* because of maternal SU [77]. Given the observed associations between brain volume and executive functioning [78], future modelling that includes tests of causal hypotheses versus non-causal but correlated genetic risks should be a public health priority. Such data would enable individuals to make informed cost–benefit judgements regarding the consequences of SU, as well influence rational law-making.

**CONCLUSION**

In the context of expanding medicalization and decriminalization and concerns surrounding the consequences of increased availability, cannabis use is unrelated to any subcortical region of interest. However, maximum nicotine use was associated with significantly smaller thalamus volumes, but only in middle-aged males. Other MRI phenotypes such as cortical and white matter measures need to be investigated and the putative associations between cortical regions and substance use explored. MRI measures combined with genetically informative cross-panel longitudinal designs [79] are necessary to resolve critical questions of causality, sources of genetic and environmental covariance and whether or not the putative causal effects of SU on brain morphology are reversible. The recently announced NIH programme, ‘Adolescent Brain and Cognitive Development’, which plans to study prospectively 10 000 youth aged 10–20 years, has the potential to explore the hypotheses generated by our findings.

**Declaration of interests**

None.

**Acknowledgements**

This study was supported by US National Institute of Health grants: R00DA023549; DA-18673; NIA R01 AG018384; R01 AG018386; R01 AG022381; R01 AG022982; R01 DA025109 05; R01 HD050735; K08 AG047903; R03 AG 046413; U54 EB020403; and R01 HD050735-01A2. This study was also supported by Australia National Health and Medical Research Council (NHMRC) grants: 496682; 1009064; 1009064; and 49662 and the VA San Diego Center of Excellence for Stress
and Mental Health. J.J.McG. was funded by the NHMRC John Cade Fellowship: APP1056929. N.A.G. had full access to all the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References


1672 Nathan A. Gillespie et al.


Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article.

Table S1 Univariate model comparisons for multi-substance use along with standardized proportions of variance.